Hyperglycaemia is common in patients who are admitted to hospital with acute coronary syndrome. In the Euro Heart Survey on diabetes, 22% of people admitted to hospital as emergency cases because of coronary artery disease were found to have undiagnosed diabetes after a glucose tolerance test, with a further 36% found to have impaired glucose tolerance.
1 Hyperglycaemia is a powerful predictor of poorer survival and increased risk of complications while in hospital.
2 3 Despite this, hyperglycaemia remains under-recognised as a risk factor for acute coronary syndrome and is often untreated. 4 This article summarises the recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of hyperglycaemia within the first 48 hours of a patient's admission to hospital for acute coronary syndrome. 
Overcoming barriers
Healthcare professionals may question the value of a negative recommendation-in this case, to avoid routine use of intensive insulin therapy in the management of hyperglycaemia in patients admitted to hospital for acute coronary syndrome. However, it is important to ensure that treatments such as intensive insulin therapy that are no better than standard care (for example, a dose adjusted insulin infusion) and are associated with risks such as hypoglycaemia are not routinely used in clinical practice unless it is clinically indicated. The guideline also prompts healthcare professionals to consider the long term risk of patients without known diabetes developing diabetes. Although communication with primary care practitioners may be perceived as time consuming, it may improve long term monitoring of high risk patients.
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Further information on the guidance
This guidance was developed by the Short Clinical Guidelines Technical Team at NICE in accordance with NICE guideline development methods (www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009. jsp). The Guideline Development Group included a range of healthcare professionals including a general practitioner, two cardiologists, two physicians, a specialist diabetes nurse, and a patient. Four key clinical questions were formulated, and the evidence was analysed and appraised using GRADE methodology for assessing the quality of evidence where appropriate (www.gradeworkinggroup.org). The cost effectiveness of intensive insulin therapy was also assessed. The draft guideline underwent a rigorous validation process, which included inviting stakeholder organisations to comment. The guideline group took all comments into consideration when producing the final version of the guideline.
NICE has produced three different versions of the guideline: a full version containing all the evidence, the process undertaken to develop the recommendations, and all the recommendations; a quick reference guide; and a version for patients and the public. All these versions are available from the NICE website (www.nice.org.uk). The guideline will be reviewed for an update in three years as part of the NICE guideline development programme.
Future research
The guideline recommends that a large randomised controlled trial is conducted for people with acute coronary syndrome and hyperglycaemia. This study should assess the effectiveness and safety of intravenous or subcutaneous insulin compared with standard care (a dose adjusted insulin infusion) to achieve blood glucose concentrations between 6 mmol/L and 11 mmol/L for at least 24 hours.
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